There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
Stock Information for NanoViricides Inc.
Loading
Please wait while we load your information from QuoteMedia.